Treatment Resistant Depression
Many pharmaceutical companies have reduced or completely withdrawn their interest in anxiety disorder/depression drug discovery in the last 5-6 years. This has reflected the difficulty of prosecuting a clinical trial that demonstrates a clear advantage over the existing generic medications (e.g. benzodiazepines and SSRIs).
However, other pharmacological mechanisms, not directly targeting the monoaminergic systems (e.g. ketamine-like), are currently emerging and under investigation for the development of novel antidepressant drugs. The development of such NCEs is aimed to treat patients showing resistance to conventional antidepressants including SSRIs. It is for this reason that Transpharmation has not sought to establish many of the ‘commodity’ assays offered by many of the non-specialist preclinical CROs. We have concentrated in an area of interest to our clients; treatment resistant depression. We offer a unique service based on endogenous models of Treatment Resistant Depression which can be coupled with behavioural, electrophysiological and molecular biomarkers assays.
|Contact us for a full dataset on Treatment Resistant Depression.|